Alpha Tau Medical Treats First Recurrent Lung Cancer Patient
Ticker: DRTSW · Form: 6-K · Filed: Oct 10, 2024 · CIK: 1871321
| Field | Detail |
|---|---|
| Company | Alpha Tau Medical Ltd. (DRTSW) |
| Form Type | 6-K |
| Filed Date | Oct 10, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: medical-technology, clinical-trial, press-release
TL;DR
Alpha Tau Medical just treated its first recurrent lung cancer patient. Big step for their tech.
AI Summary
On October 10, 2024, Alpha Tau Medical Ltd. announced it has treated the first patient with its innovative technology for recurrent lung cancer. This milestone marks a significant step in the company's efforts to address challenging oncological conditions.
Why It Matters
This marks a clinical advancement for Alpha Tau Medical, potentially opening new treatment avenues for patients with recurrent lung cancer.
Risk Assessment
Risk Level: medium — Clinical trial progress and regulatory approvals are inherently uncertain, and market adoption of new medical technologies can be slow.
Key Players & Entities
- Alpha Tau Medical Ltd. (company) — Registrant
- October 10, 2024 (date) — Announcement date
- 9777605 (other) — ZIP code
FAQ
What specific technology did Alpha Tau Medical use to treat the recurrent lung cancer patient?
The filing states that Alpha Tau Medical treated the first patient with recurrent lung cancer, but does not specify the exact technology used in this particular instance, referring to an attached press release for details.
Where is Alpha Tau Medical Ltd. headquartered?
Alpha Tau Medical Ltd.'s principal executive offices are located at Kiryat HaMada St. 5, Jerusalem, Israel, 9777605.
What is the Commission File Number for Alpha Tau Medical Ltd.?
The Commission File Number for Alpha Tau Medical Ltd. is 001-41316.
What form does this filing represent?
This filing is a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Section 13A-16 or 15D-16 under the Securities Exchange Act of 1934.
When was this Form 6-K filed?
This Form 6-K was filed on October 10, 2024.
Filing Stats: 297 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-10-10 08:32:02
Filing Documents
- ea021725301-6k_alpha.htm (6-K) — 12KB
- ea021725301ex99-1_alpha.htm (EX-99.1) — 13KB
- 0001213900-24-086731.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alpha Tau Medical Ltd. Date: October 10, 2024 By: /s/ Uzi Sofer Uzi Sofer Chief Executive Officer 2